COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines
- PMID: 33629336
- DOI: 10.26355/eurrev_202102_24877
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines
Abstract
Objective: The "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" disease has caused a worldwide challenging and threatening pandemic (COVID-19), with huge health and economic losses. The US Food and Drug Administration, (FDA) has granted emergency use authorization for treatment with the Pfizer/BioNTech and Moderna COVID-19 vaccines. Many people have a history of a significant allergic reaction to a specific food, medicine, or vaccine; hence, people all over the world have great concerns about these two authorized vaccines. This article compares the pharmacology, indications, contraindications, and adverse effects of the Pfizer/BioNTech and Moderna vaccines.
Materials and methods: The required documents and information were collected from the relevant databases, including Web of Science (Clarivate Analytics), PubMed, EMBASE, World Health Organization (WHO), Food and Drug Authorities (FDA) USA, Local Ministries, Health Institutes, and Google Scholar. The key terms used were: Coronavirus, SARS-COV-2, COVID-19 pandemic, vaccines, Pfizer/BioNTech vaccine, Moderna vaccine, pharmacology, benefits, allergic responses, indications, contraindications, and adverse effects. The descriptive information was recorded, and we eventually included 12 documents including research articles, clinical trials, and websites to record the required information.
Results: Based on the currently available literature, both vaccines are beneficial to provide immunity against SARS-CoV-2 infection. Pfizer/BioNTech Vaccine has been recommended to people 16 years of age and older, with a dose of 30 μg (0.3 m) at a cost of $19.50. It provides immunogenicity for at least 119 days after the first vaccination and is 95% effective in preventing the SARS-COV-2 infection. However, Moderna Vaccine has been recommended to people 18 years of age and older, with a dose of 50 μg (0.5 mL) at a cost of $32-37. It provides immunogenicity for at least 119 days after the first vaccination and is 94.5% effective in preventing the SARS-CoV-2 infection. However, some associated allergic symptoms have been reported for both vaccines. The COVID-19 vaccines can cause mild adverse effects after the first or second doses, including pain, redness or swelling at the site of vaccine shot, fever, fatigue, headache, muscle pain, nausea, vomiting, itching, chills, and joint pain, and can also rarely cause anaphylactic shock. The occurrence of adverse effects is reported to be lower in the Pfizer/BioNTech vaccine compared to the Moderna vaccine; however, the Moderna vaccine compared to the Pfizer vaccine is easier to transport and store because it is less temperature sensitive.
Conclusions: The FDA has granted emergency use authorization for the Pfizer/BioNTech and Moderna COVID-19 vaccines. These vaccines can protect recipients from a SARS-CoV- 2 infection by formation of antibodies and provide immunity against a SARS-CoV-2 infection. Both vaccines can cause various adverse effects, but these reactions are reported to be less frequent in the Pfizer/BioNTech vaccine compared to the Moderna COVID-19 vaccine; however, the Moderna vaccine compared to the Pfizer vaccine is easier to transport and store because it is less temperature sensitive.
Similar articles
-
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1):e1104. doi: 10.1212/NXI.0000000000001104. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34753828 Free PMC article.
-
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1094-1099. doi: 10.15585/mmwr.mm7032e4. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34383735 Free PMC article.
-
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34437519 Free PMC article.
-
COVID-19 Vaccines.2024 Jun 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Jun 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 33355732 Free Books & Documents. Review.
-
Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.Clin Drug Investig. 2021 Jun;41(6):499-509. doi: 10.1007/s40261-021-01022-9. Epub 2021 Mar 23. Clin Drug Investig. 2021. PMID: 33754328 Free PMC article. Review.
Cited by
-
COVID-19 vaccination and menstrual disturbances: A prospective study from Pakistan.Pak J Med Sci. 2024 Aug;40(7):1345-1348. doi: 10.12669/pjms.40.7.8709. Pak J Med Sci. 2024. PMID: 39092064 Free PMC article.
-
Nonattendance is associated with work performance due to the side effects of COVID-19 vaccination: a cross-sectional study in a Japanese manufacturing industry.J Occup Health. 2024 Jan 4;66(1):uiae030. doi: 10.1093/joccuh/uiae030. J Occup Health. 2024. PMID: 38865583 Free PMC article.
-
An Autopsy Case of Reversible Cerebral Vasoconstriction Syndrome After a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination.Cureus. 2024 Apr 29;16(4):e59311. doi: 10.7759/cureus.59311. eCollection 2024 Apr. Cureus. 2024. PMID: 38817496 Free PMC article.
-
A study on the side effects caused by the Pfizer/BioNTech COVID-19 vaccine: Focus on IgG antibodies and serological biomarkers.Cent Eur J Immunol. 2024;49(1):2-10. doi: 10.5114/ceji.2024.136382. Epub 2024 Apr 9. Cent Eur J Immunol. 2024. PMID: 38812603 Free PMC article.
-
Short-term side effects of BNT162b2 vaccine in primary care settings in Qatar: a retrospective study.Front Public Health. 2024 Apr 10;12:1384327. doi: 10.3389/fpubh.2024.1384327. eCollection 2024. Front Public Health. 2024. PMID: 38660363 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous